TrialThe Lancet. Infectious diseases2021

Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.

Judith Absalon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.